Vaccination against COVID-19 in a post-pandemic era DOI
Felippe Lazar Neto, Adrián Ceccato, Otávio T. Ranzani

et al.

European Respiratory Society eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 27, 2024

Language: Английский

Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study DOI Creative Commons
Freja Kirsebom, Julia Stowe, Jamie Lopez Bernal

et al.

Journal of Infection, Journal Year: 2024, Volume and Issue: 89(1), P. 106177 - 106177

Published: May 7, 2024

The last COVID-19 vaccine offered to all adults in England became available from November 2021. most recent booster programme commenced September 2023. Bivalent BA.4-5 or monovalent XBB.1.5 boosters were given. During the study period, JN.1 variant dominant England.

Language: Английский

Citations

15
Morris responds to “Critical analyses concerning COVID-19 vaccines need to be consistently critical, and informed” DOI
Jeffrey S. Morris

American Journal of Epidemiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Language: Английский

Citations

0
COVID-19 Vaccine Effectiveness and Risk Factors of Booster Failure in 480,000 Patients with Diabetes Mellitus: A Population-Based Cohort Study DOI Creative Commons
Maria Christina L. Oliveira, Daniella Reis Barbosa Martelli, Ana Cristina Simões e Silva

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(5), P. 979 - 979

Published: April 24, 2025

To investigate the real-world effectiveness of COVID-19 vaccines in a large cohort patients with diabetes mellitus (DM), we analyzed all >18-year-old registered Brazilian nationwide surveillance database between February 2020 and 2023. The primary outcome interest was vaccine against death, evaluated using multivariate logistic regression models. Among 2,131,089 SIVEP-Gripe, 482,677 (22.6%) had DM. After adjusting for covariates, DM higher risk death than those without comorbidities (adjusted odds ratio [aOR] = 1.43, 95% CI, 1.39–1.47). For (72.7%, 70.5–74.7) (73.4%, 68.2–76.7), similar after booster dose. However, it reduced associated other (60.5%; 57.5–63.2). strongest factor failure omicron variant (aOR 27.8, 19.9–40.1). Our study revealed that provided robust protection individuals our findings underscore need to update develop tailored strategies diabetes, especially additional underlying conditions.

Language: Английский

Citations

0
The impact of COVID-19 vaccine spring boosters on COVID-19 hospital admissions in England 2022/23 DOI Creative Commons
Nick Andrews, Itunu G. Osuntoki, Julia Stowe

et al.

Journal of Infection, Journal Year: 2024, Volume and Issue: 89(3), P. 106221 - 106221

Published: July 10, 2024

Language: Английский

Citations

1
Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies DOI Creative Commons
Palaniyandi Muthukutty, Jaime MacDonald, So Young Yoo

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1220 - 1220

Published: Oct. 27, 2024

Emerging viral diseases, including seasonal illnesses and pandemics, pose significant global public health risks. Respiratory viruses, particularly coronaviruses influenza are associated with high morbidity mortality, imposing substantial socioeconomic burdens. This review focuses on the current landscape of respiratory SARS-CoV-2, their antiviral treatments. It also discusses potential for pandemics development new vaccines therapies, drawing lessons from past outbreaks to inform future strategies managing threats.

Language: Английский

Citations

1
Vaccination against COVID-19 in a post-pandemic era DOI
Felippe Lazar Neto, Adrián Ceccato, Otávio T. Ranzani

et al.

European Respiratory Society eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 27, 2024

Language: Английский

Citations

0